Anticholinergic medication use and cognitive impairment in the older population: The medical research council cognitive function and ageing study

Journal of the American Geriatrics Society

Volumn 59, Issue 8, 2011, Pages 1477-1483

  Fox, Chris ^a   Richardson, Kathryn ^b   Maidment, Ian D ^c,d   Savva, George M ^e   Matthews, Fiona E ^f   Smithard, David ^g,h   Coulton, Simon ^d   Katona, Cornelius ⁱ   Boustani, Malaz A ^j,k   Brayne, Carol ^b,e  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d KENT AND MEDWAY NHS AND SOCIAL CARE PARTNERSHIP TRUST   (United Kingdom)

^e UNIVERSITY OF KENT   (United Kingdom)

^f MEDICAL RESEARCH COUNCIL   (United Kingdom)

^g KENT COMMUNITY HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^h University College London ^*  (United Kingdom)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j INDIANA UNIVERSITY   (United States)

^k REGENSTRIEF INSTITUTE   (United States)

more..

Author keywords

anticholinergic activity; cognitive impairment; elderly

Indexed keywords

AMITRIPTYLINE; ATENOLOL; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DEXTROPROPOXYPHENE; FUROSEMIDE; NIFEDIPINE;

AGED; ANTICHOLINERGIC EFFECT; ARTICLE; COGNITIVE DEFECT; COMORBIDITY; DAILY LIFE ACTIVITY; DOSE RESPONSE; DRUG USE; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; GENDER; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PRESCRIPTION; SOCIAL CLASS;

AGED; AGED, 80 AND OVER; CHOLINERGIC ANTAGONISTS; COGNITION DISORDERS; COMORBIDITY; ENGLAND; FEMALE; GERIATRIC ASSESSMENT; HEALTH SURVEYS; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL STATUS SCHEDULE; ODDS RATIO; PROSPECTIVE STUDIES; PSYCHOMETRICS; RISK FACTORS; WALES;

EID: 79960941923     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2011.03491.x     Document Type: Article

References (29)

1. Boustani M, Ham RJ., Alzheimer disease and other dementias. In:, Ham RJ, Sloane PD, Warshaw GA, Bernard MA, Flaherty E, editors. Primary Care Geriatrics, a Case-Based Approach, 5th Ed. Philadelphia: Mosby Elsevier, 2007, pp 219-236.
2. Hanlon JT, Schamder KE, Boult C, et al,. Use of inappropriate prescription drugs by older people. J Am Geriatr Soc 2002; 50: 26-34. (Pubitemid 34053019)
3. Boustani MA, Campbell NL, Munger S, et al,. Impact of anticholinergics on the aging brain: A review and practical application. Aging Health 2008; 4: 311-320.
4. Boustani M, Hall KS, Lane KA, et al,. The association between cognition and histamine-2 receptor antagonists in African Americans. J Am Geriatr Soc 2007; 55: 1248-1253. (Pubitemid 47106699)
5. Castelino RL, Bajorek BV, Chen TF., Targeting suboptimal prescribing in the elderly: A review of the impact of pharmacy services. Ann Pharmacother 2009; 43: 1096-1106.
6. Campbell NL, Boustani MA, Lane KA, et al,. Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology 2010; 75: 152-159.
7. Carriere I, Fourrier-Reglat A, Dartigues JF, et al,. Drugs with anticholinergic properties, cognitive decline, dementia in an elderly general population-the 3-City study. Arch Intern Med 2009; 169: 1317-1324.
8. Aigner TG, Mishkin M., The effects of physostigmine and scopolamine on recognition memory in monkeys. Behav Neural Biol 1986; 45: 81-87. (Pubitemid 16162297)
9. Fibiger HC, Damsma G, Day JC., Behavioral pharmacology and biochemistry of central cholinergic neurotransmission. Adv Exp Med Biol 1991; 295: 399-414.
10. Miller EK, Desimone R., Scopolamine affects short-term memory but not inferior temporal neurons. Neuroreport 1993; 4: 81-84. (Pubitemid 23066396)
11. Haroutunian V, Greig N, Pei XF, et al,. Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. Brain Res Mol Brain Res 1997; 46: 161-168. (Pubitemid 27214367)
12. Haring R, Fisher A, Marciano D, et al,. Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the m1 muscarinic receptor to β-amyloid protein secretion. J Neurochem 1998; 71: 2094-2103. (Pubitemid 28491566)
13. Allinson TM, Parkin ET, Turner AJ, et al,. ADAMs family members as amyloid precursor protein α-secretases. J Neurosci Res 2003; 74: 342-352. (Pubitemid 37362810)
14. Campbell N, Boustani M, Limbil T, et al,. The cognitive impact of anticholinergics: A clinical review. Clin Interv Aging 2009; 4: 225-233.
15. MRC CFAS Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing study (MRC CFAS). Lancet 2001; 357: 169-175.
16. MRC CFAS. Cognitive function and dementia in six areas of England and Wales: The distribution of MMSE and prevalence of GMS organicity level in the MRC CFA Study. The Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Psychol Med 1998; 28: 319-335.
17. Chen YF, Dewey ME, Avery AJ., Self-reported medication use for older people in England and Wales. J Clin Pharm Ther 2001; 26: 129-140. (Pubitemid 32336729)
18. NHS Centre for Coding and Classification The Read Codes: Drug and Appliance Dictionary General Information. Loughborough, UK: NHS Centre for Coding and Classification, 1998.
19. Tune LE, Egeli S., Acetylcholine and delirium. Dement Geriatr Cogn Dis 1999; 10: 342-344. (Pubitemid 29403592)
20. Broks P, Preston GC, Traub M, et al,. Modeling dementia: Effects of scopolamine on memory and attention. Neuropsychologia 1988; 26: 685-700.
21. Beatty WW, Butters N, Janowsky DS., Patterns of memory failure after scopolamine treatment: Implications for cholinergic hypotheses of dementia. Behav Neur Biol 1986; 45: 196-211. (Pubitemid 16164035)
22. Itil T, Fink M., Anticholinergic drug-induced delirium: Experimental modification, quantitative EEG, and behavioral correlations. J Nerv Ment Dis 1966; 143: 492-507.
23. Ancelin ML, Artero S, Portet F, et al,. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: Longitudinal cohort study. BMJ 2006; 332: 455-459.
24. Roe C, Anderson M, Spivack B., Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc 2002; 50: 836-842. (Pubitemid 34496679)
25. Bottigi KA, Salazar JC, Yu L, et al,. Long-term cognitive impact of anticholinergic medications in older adults. Am J Geriatr Psychiatry 2006; 14: 980-984. (Pubitemid 44706417)
26. Murray MD, Lane KA, Gao S, et al,. Preservation of cognitive function with antihypertensive medications: A longitudinal analysis of a community-based sample of African Americans. Arch Intern Med 2002; 162: 2090-2096. (Pubitemid 35168217)
27. Cacciatore F, Abete P, Ferrara N, et al,. Congestive heart failure and cognitive impairment in an older population. Osservatorio Geriatrico Campano Study Group. J Am Geriatr Soc 1998; 46: 1343-1348. (Pubitemid 28511873)
28. Chew ML, Mulsant BH, Pollock BG, et al,. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 2008; 56: 1333-1341.
29. Thomas C, Hesterman U, Kopitz J, et al,. Serum anticholinergic activity and cerebral cholinergic dysfunction: An EEG study in frail elderly with and without delirium. BMC Neurosci 2008; 9: 1-10.